Format

Send to

Choose Destination
Thromb Res. 2016 Apr;140 Suppl 1:S154-9. doi: 10.1016/S0049-3848(16)30115-3.

The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs?

Author information

1
Marie Curie Palliative Care Research Centre, Cardiff University, Cardiff Wales, United Kingdom. Electronic address: Simon.Noble@wales.nhs.uk.
2
Royal Gwent Hospital, Newport, Wales, United Kingdom.

Abstract

Whilst the term cancer associated thrombosis (CAT) offers an overarching term for all thrombotic events encountered during the cancer journey, the reality is that this is a far too simplistic reflection of a complex multifactorial process occurring within a heterogeneous population. The management of CAT needs to consider factors beyond the thrombus itself: patients must be treated as individuals within the context of their own cancer journey and their preferences for different treatment options. The breath of pathological, pharmacological and psychosocial variants means it is highly unlikely that one treatment regime will be appropriate for all patients. It is inevitable that regimes may need to be modified and anticoagulant agents changed according to clinical and patient preference needs. There is strong evidence supporting the use of low molecular weight heparin first line in the treatment of acute CAT. The evidence for warfarin and the direct acting oral anticoagulants is not as strong but, as oral agents, may be preferred by some patients. This paper shall identify the various treatment options available, factors which will influence the decision making process and when it is justifiable to treat patients differently to the established protocol.

KEYWORDS:

Cancer associated thrombosis; DOACs; Individual care; LMWH; Patient preference

PMID:
27067970
DOI:
10.1016/S0049-3848(16)30115-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center